Literature DB >> 7696235

Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa.

S Hayasaka1, M Fujii, Y Yamamoto, S Noda, H Kurome, M Sasaki.   

Abstract

A total of 43 patients (86 eyes) with chronic viral hepatitis were examined prospectively before and after the start of interferon therapy. Of 37 non-diabetic patients, 23 (group A1) did not have retinopathy or subconjunctival haemorrhage, 11 (group A2) developed retinopathy, and three (group A3) exhibited subconjunctival haemorrhage during the treatment. In most eyes, the retinopathy disappeared after therapy was stopped. Of six diabetic patients, three (group B1) developed retinopathy and three (group B2) showed progression of existing retinopathy. Thrombocytopenia was not associated with the retinopathy in any patient. The patients' good visual acuity remained unchanged, even after retinal changes appeared. Ophthalmologists should be aware that retinopathy and subconjunctival haemorrhage may develop in patients with chronic viral hepatitis receiving interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7696235      PMCID: PMC505046          DOI: 10.1136/bjo.79.2.150

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  2 in total

1.  Interferon-associated retinopathy.

Authors:  D R Guyer; J Tiedeman; L A Yannuzzi; J S Slakter; D Parke; J Kelley; R A Tang; M Marmor; G Abrams; J W Miller
Journal:  Arch Ophthalmol       Date:  1993-03

2.  Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration.

Authors:  L S Poliner; P E Tornambe; P E Michelson; J G Heitzmann
Journal:  Ophthalmology       Date:  1993-09       Impact factor: 12.079

  2 in total
  16 in total

Review 1.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

2.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

3.  Bell's palsy and choreiform movements during peginterferon alpha and ribavirin therapy.

Authors:  Sener Barut; Hatice Karaer; Erol Oksuz; Asli Gündoğdu Eken; Ayse Nazli Basak
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

4.  Ophthalmological side effects of interferon therapy of chronic hepatitis C.

Authors:  Eman Medhat; Gamal Esmat; Eman Hamza; Amr Abdel Aziz; Waleed Fouad Fathalah; Samar Kamal Darweesh; Zeinab Zakaria; Sameh Mostafa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

Review 5.  Interferon associated retinopathy.

Authors:  S Hayasaka; Y Nagaki; M Matsumoto; S Sato
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

6.  Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Yoshihiko Nagase; Yuhtaro Kobayashi; Kiyomi Yasuda; Kazuhiko Koike; Shiro Iino; Michihiro Suzuki; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 7.  Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.

Authors:  V Peponis; V C Kyttaris; S E Chalkiadakis; S Bonovas; N M Sitaras
Journal:  Lupus       Date:  2010-02-09       Impact factor: 2.911

8.  Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.

Authors:  Ei Tae Kim; Lee Hoo Kim; Jung Il Lee; Hee Seung Chin
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

Review 9.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  New roles for the major human 3'-5' exonuclease TREX1 in human disease.

Authors:  David Kavanagh; Dirk Spitzer; Parul H Kothari; Aisha Shaikh; M Kathryn Liszewski; Anna Richards; John P Atkinson
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.